Genomic differences in breast cancers in African American women identified
the ONA take:
Differences in breast cancer recurrence and survival between African American women and white women are well established; however, what drives those differences is not well known.
In this paper, published online in the Journal of Clinical Oncology, investigators describe genomic differences in the tumors of the two groups of women that may explain those disparities.
The impact of socioeconomic factors such as income, health insurance, and access to health services contributes to disparities in recurrence and survival for African American women with breast cancer. Those factors, however, do not explain the whole difference.
The investigators analyzed whole-exome sequencing data from the National Cancer Institute’s Cancer Genome Atlas culled from the tumors of 105 African American women and 664 white women whose breast cancers were diagnosed between 1988 and 2013.
The five most prevalent tumor-specific mutations were the same for both groups, but more African American women’s tumors were driven by the TP53 mutation and the PIK3CA mutation was more common in the white women’s tumors.
Additional factors were found that suggest more aggressive cancers, such as prevalence of the basal-like and mesenchymal stem-like subtypes and the number of mutations within each tumor, were greater in African American women’s tumors.
Basal subtype tumors or those driven by the TP53 mutation were factors in faster tumor recurrence, and also more likely among African American women.
Differences in breast cancer recurrence and survival between African American women and white women are well established.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Nut Consumption Inversely Associated With Lung Cancer Risk
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- National Health Care Spending Expected to Grow Five Percent Annually
- Patients With Urologic Cancer Need Psycho-oncologic Support to Manage High Stress
- 1 Year of Adjuvant Trastuzumab Improves Long-Term DFS in Early Breast Cancer
- Lenalidomide Maintenance Appears Efficacious for Relapsed DLBCL
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|